“Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data”, J of Skin, vol. 3, no. 2, p. 169, Mar. 2019, doi: 10.25251/skin.3.2.9.